Intest Res > Volume 16(4); 2018 > Article |
|
FINANCIAL SUPPORT
The authors received no financial support for the research, authorship, and/or publication of this article.
CONFLICT OF INTEREST
All authors declare that they have no conflicts of interest with respect to this work. Dr. Rupert Wing Loong Leong reports advisory board membership from Takeda, Janssen, AbbVie, MSD, Pfizer, Ferring and Aspen unrelated to this research.
AUTHOR CONTRIBUTION
Conceptualization: JP, AC, RL. Methodology: JP, AC, RL, CC, GC, WLT. Formal analysis: JP, AC, RL, FK, NM, WLT, VK. Project administration: RL, GC, WLT, CC Visualization: JP, AC. Writing - original draft: JP, AC RL, FK, GC. Writing - review and editing: JP, RL, FK, VK, CC, WT, NM, GC. Approval of final manuscript: all authors.
Adherent subjects (n=131) | Non-adherent subjects (n=42)a | P-value | |
---|---|---|---|
Demographic | |||
Age (yr) | 39 (26.5 to 51.5) | 42 (30.75 to 53.25) | 0.690 |
Female sex | 65 (49.6) | 24 (57.1) | 0.400 |
CD | 79 (60.3) | 19 (45.2) | 0.090 |
Referral hospital clinic attendance | 86 (65.6) | 5 (59.5) | 0.470 |
Married/relationship | 70 (53.4) | 24 (57.1) | 0.680 |
Crohn's and Colitis Australia membership | 16 (12.2) | 8 (19.0) | 0.260 |
Previous IBD related hospitalization | 52 (39.7) | 15 (35.7) | 0.640 |
Previous IBD related surgery | 26 (19.8) | 9 (21.4) | 0.820 |
Medication regimen | |||
Mesalazine | 73 (55.7) | 29 (69.0) | 0.130 |
Immunomodulator | 76 (58.5) | 19 (45.2) | 0.150 |
Corticosteroid | 31 (23.7) | 9 (21.4) | 0.760 |
Anti-tumor necrosis factor α agent | 32 (24.4) | 5 (11.9) | 0.085 |
Key questionnaire outcome measures | |||
High medication concerns | 58 (44.3) | 31 (73.8) | 0.001 |
High medication necessity | 121 (92.4) | 33 (78.6) | 0.013 |
Medication acceptance | 66 (50.4) | 8 (19.0) | <0.001 |
Disability (IBD-DI score <3.5) | 94 (71.8) | 38 (90.5) | 0.013 |
IBD-DI (score) | -2 (-9 to 5) | -16 (-26 to -6) | <0.001 |
Median difference in IBD-DI score | P-value | |
---|---|---|
Socio-demographic | ||
Age | -0.032a | 0.670 |
Female sex | -7.0 | 0.002 |
Married/relationship | -1.0 | 0.700 |
Crohn's & Colitis Australia membership | -1.5 | 0.730 |
Tertiary IBD clinic management | -5.5 | <0.001 |
Disease characteristics | ||
Diagnosis greater than 5 years ago | -3.0 | 0.390 |
UC diagnosis | 1.0 | 0.405 |
Previous IBD related hospitalization | -4.5 | 0.010 |
Previous surgery | -4.0 | 0.035 |
Treatment modalities | ||
5-ASA | 0.5 | 0.500 |
Immunomodulator | -1.0 | 0.450 |
Steroids | -5.5 | 0.007 |
Biologicals | 2.0 | 0.770 |
Beliefs about medications | ||
High concerns | -5.0 | <0.001 |
Low necessity | 4.0 | 0.800 |
Lack of acceptance | -7.5 | <0.001 |
Medication related behavior | ||
Non-adherence | -14.0 | <0.001 |